Skip to main content
Premium Trial:

Request an Annual Quote

Compugen's Q4 Loss Rises 23 Percent

NEW YORK (GenomeWeb News) – Compugen today reported a 23 percent increase in its fourth-quarter loss and "insignificant" revenues of $11,000 for the three-month period ended Dec. 31.

The Tel Aviv, Israel-based computational biology firm said that its revenues declined from $90,000 for the fourth quarter of 2007.

Compugen hopes to drive revenue growth through "the next, and perhaps most important stage of our commercial development" by signing "broader, more strategic types of collaborations, in comparison to the largely product candidate specific agreements we have signed to date," said President and CEO Martin Gerstel.

Compugen's net loss for the quarter was $3.8 million, or $.13 per share, compared with a net loss of $3.1 million, or $.11 per share, for the fourth quarter of 2007.

The firm's R&D spending declined 11 percent year over year to $2.5 million from $2.8 million, while its SG&A spending increased 18 percent to $1.3 million from $1.1 million.

For full-year 2008, Compugen brought in revenues of $338,000, versus $180,000 in 2007. Its net loss for the year increased around 3 percent to $12.5 million, or $.44 per share, from $12.1 million, or $.43 per share.

Its R&D expenses decreased around 4 percent to $9.3 million from $9.7 million, and its SG&A spending increased roughly 5 percent to $4.5 million from $4.3 million.

Compugen finished the year with $7.2 million in cash, cash equivalents, short-term deposits, and marketable securities. The firm noted that it had previously projected net cash requirements of less than $8 million to support its operations through 2009.

Filed under

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.